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Background: There is a great interest in studying phosphotyrosine dependent protein-protein interactions in
tyrosine kinase pathways that play a critical role in many aspects of cellular function. We previously established SH2
profiling, a phosphoproteomic approach based on membrane binding assays that utilizes purified Src Homology 2
(SH2) domains as a molecular tool to profile the global tyrosine phosphorylation state of cells. However, in order to
use this method to investigate SH2 binding sites on a specific target in cell lysate, additional procedures such as
pull-down or immunoprecipitation which consume large amounts of sample are required.
Results: We have developed PLA-SH2, an alternative in-solution modular domain binding assay that takes
advantage of Proximity Ligation Assay and real-time PCR. The SH2-PLA assay utilizes oligonucleotide-conjugated
anti-GST and anti-EGFR antibodies recognizing a GST-SH2 probe and cellular EGFR, respectively. If the GST-SH2 and
EGFR are in close proximity as a result of SH2-phosphotyrosine interactions, the two oligonucleotides are brought
within a suitable distance for ligation to occur, allowing for efficient complex amplification via real-time PCR. The
assay detected signal across at least 3 orders of magnitude of lysate input with a linear range spanning 1–2 orders
and a low femtomole limit of detection for EGFR phosphotyrosine. SH2 binding kinetics determined by PLA-SH2
showed good agreement with established far-Western analyses for A431 and Cos1 cells stimulated with EGF at
various times and doses. Further, we showed that PLA-SH2 can survey lung cancer tissues using 1 μl lysate without
requiring phospho-enrichment.
Conclusions: We showed for the first time that interactions between SH2 domain probes and EGFR in cell lysate
can be determined in a microliter-scale assay using SH2-PLA. The obvious benefit of this method is that the low
sample requirement allows detection of SH2 binding in samples which are difficult to analyze using traditional
protein interaction assays. This feature along with short assay runtime makes this method a useful platform for the
development of high throughput assays to determine modular domain–ligand interactions which could have
wide-ranging applications in both basic and translational cancer research.
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An important consequence of reversible phosphorylation
of tyrosine residues on proteins is the creation of bind-
ing sites for phosphotyrosine recognizing domains such
as Src homology 2 (SH2) and phosphotyrosine binding
(PTB) domains [1, 2]. The human proteome contains* Correspondence: machida@uchc.edu
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protein interactions mediated by SH2 domains play a
critical role in essential cellular processes such as cell
growth, migration, differentiation, and survival [3, 4].
We and others have utilized SH2 domains as a tool to
profile the global tyrosine phosphorylation state of cells
[5–9]. SH2 profiling is a unique proteomic method in
which interactions between an array of SH2 domains
and protein samples are quantitatively analyzed, thereby
defining the functional output of tyrosine phosphoryl-
ation. There are three assay platforms for SH2 profiling:ss article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
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tagged multiplex (OTM) assays [10]. In far-Western,
protein samples are separated by electrophoresis and
replicate blots are separately probed with labeled SH2
domains [6, 9]. In rosette assay, samples are spotted on a
membrane, and the binding assay is carried out in a
96-well plate [7]. The labeled SH2 domain probes are
incubated with multiple sample spots in a noncompetitive
manner (single SH2 per well). In an oligonucleotide-
tagged multiplex (OTM) assay, a mixture of SH2 domains
with domain-specific DNA tags are incubated with a sam-
ple spot allowing for competitive binding (single sample
per well) [8]. Signal is detected either by chemilumines-
cence (far-Western and rosette) or by PCR (OTM). Quan-
tified values are used to classify samples, such as different
cancer tissues, based on SH2 binding preferences (SH2
profiles) [5, 6, 9, 10].
One limitation of current SH2 profiling methods is
that these assays themselves do not provide the identity
of the binding proteins. When the sample identity is
known, such as synthesized peptides or purified proteins,
this is not a problem. However, for samples with more
complexity such as cell lysate and tissue, it is often difficult
to infer the identity of detected SH2 binding proteins
unless a literature/database search can provide a helpful
clue. In this case, additional experimental methods such
as antibody-based or mass spectrometry-based protein
identification must be combined with SH2 profiling. For
example, in order to identify a band detected by SH2-far-
Western, a pull down assay combined with Western blot-
ting with specific antibodies (for few candidate proteins)
or MS identification (for an unknown set of proteins) is
needed [5, 7]. Further, those additional assays often re-
quire a large amount of sample, are labor intensive and
not always successful [11]. These laborious, costly proce-
dures are required for even a simple task such as validat-
ing the binding of SH2 domains to a few candidate
proteins (e.g., EGFR, ErbB2, etc.) which have been inferred
from SH2 profiling.
Proximity ligation assay (PLA) is a molecular recognition
assay that depends on the ligation of two oligonucleotide-
tagged probes that are capable of forming a complex, when
binding to a target (or targets) that are in close proximity
to each other [12, 13]. The method was originally de-
scribed using aptamers as affinity reagents [14], and in its
current version is performed using antibodies to deter-
mine protein expression and interactions in situ or in
solution [15–18]. Various commercial PLA kits are avail-
able mainly from Olink Bioscience and Applied Biosystems.
Of these, Applied Biosystems TaqMan Protein Assays are
designed to quantify target protein expression levels using a
small amount of cell lysate (2–3 μl) [19, 20]. The system
uses TaqMan technology, an established platform for quan-
tification of gene expression based on quantitative real-timePCR. The standard TaqMan Protein Assay kit was origin-
ally designed to detect stem cell markers, while an open
kit is available for use with custom antibodies [20]. Al-
though homogenous PLA has been used to determine
protein expression in lysate [21, 22], we hypothesized that
the system could be customized for detection of SH2
domain-based protein-protein interactions in solution. A
PLA-based SH2 profiling method would have multiple
advantages such as low sample requirement, higher sensi-
tivity, and rapid validation of SH2 binding protein identity.
Here, using activated epidermal growth factor receptor
(EGFR) as the SH2 binding target, we have developed and
validated such an assay, termed SH2-PLA, which has a
broad range of detection, performance equivalent to




We chose the epidermoid carcinoma cell line A431,
which overexpresses wild type epidermal growth factor
receptor (EGFR), as a developmental platform. The
premise of the SH2-PLA assay is that 1) EGF stimulation
induces tyrosine phosphorylation of the intracellular do-
main of EGFR, which creates specific binding sites for
SH2 domains such as Grb2, Src, PLCγ1, Vav2, etc.; 2)
GST-SH2 domain coupled to anti-GST 5′ Prox-Oligo
binds to these phosphotyrosines in cell lysate; 3) This
interaction brings the anti-GST 5′ Prox-Oligo and anti-
EGFR 3′ Prox-Oligo probes together in close proximity,
thus allowing for the proximity ligation reaction to be
subsequently quantified by real-time PCR (Fig. 1). In
other words, detection of a specific assay signal requires
the creation of the quaternary complex: anti-EGFR 3′
Prox-Oligo probe:phosphorylated EGFR:GST-SH2 pro-
tein:anti-GST 5′ Prox-Oligo probe.
Performance of TaqMan protein expression assay
Prior to customizing the TaqMan Protein Expression
Assay for SH2-PLA (i.e., modular domain binding assay),
we tested the performance of the original proximity
ligation assay using the kit-supplied anti-ICAM1 assay
probes and Raji B-cell lymphoma lysate. The 3′ and 5′
oligonucleotide-conjugated anti-ICAM1 assay probes
were incubated with the Raji lysate for 60 min followed by
the ligation reaction. After heat inactivation, the ligation
product was quantified using the TaqMan real-time PCR
system. The experiment was performed in a 96 well plate
with approximately three hours of assay time. We ob-
served, with high-precision, approximately three orders of
magnitude of linear dynamic range for a cell input of
0.24 – 250 cells per μl (intra-assay %CV < 1.1 %) (Additional
file 1: Figure S1A). When two independent experiments
were compared, they showed very strong correlation
Fig. 1 In-solution SH2 domain binding assay using proximity ligation and real-time PCR. a, Schematic Illustration of SH2-PLA. A pair of PLA probes
is used to detect the interaction of tyrosine phosphorylated EGFR and a GST-SH2 domain. The 3′ SH2-PLA probe consists of an anti-EGFR antibody
conjugated with the 3′ proximity oligonucleotide (3′ Prox-Oligo). The 5′ SH2-PLA probes consists of an anti-GST antibody conjugated with the 5′
Prox-Oligo and a GST-SH2 domain. When the GST-SH2 domain binds to tyrosine phosphorylation sites of EGFR, the 5′ and 3′ PLA probes are brought
in close proximity, allowing ligation of the two Prox-Oligos which is detectable by real-time PCR. b, Experimental workflow of SH2-PLA Method 1.
Lysates are prepared with or without EGF stimulation. Biotinylated anti-GST and anti-EGFR antibodies are conjugated with the 5′ and 3′ Prox-Oligos,
respectively, and stored at −20 °C. The 5′ SH2-PLA probe is mixed with purified GST-SH2, and the 3′ SH2-PLA probe is mixed with cell lysates allowing
the antibodies to bind their respective epitopes. Subsequently, the 5′ and 3′ PLA probe solutions are combined to induce interaction between the
SH2 and pEGFR. Then, the amount of the complex is quantified by proximity ligation and real-time PCR. An alternative method is also possible
(Additional file 1: Figure S2). Estimated assay runtime including sample-handling steps for each procedure is noted on the right
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S1B). We concluded that the performance of the TaqMan
Protein Expression Assay was sufficient for development
of an SH2 domain binding assay.
Development of the SH2-PLA assay
Biotinylated anti-GST and anti-EGFR polyclonal anti-
bodies were conjugated with 5′ and 3′ oligonucleotides
following the probe development protocol (see Methods).
To evaluate the anti-GST probes (5′ Prox-Oligo- and
3′ Prox-Oligo-conjugated anti-GST antibodies) and
anti-EGFR probes (5′ Prox-Oligo- and 3′ Prox-Oligo-
conjugated anti-EGFR antibodies), purified GST protein
and A431 cell lysate were serially diluted and respective
TaqMan protein expression assays were performed as in
the ICAM1 expression assay. In these separate detection
experiments for GST and EGFR, we observed that the
GST probe had a linear increase in Ct values between 0.13
and 4.17 nM of GST input, while the EGFR probe for
A431 lysate was linear from 1.9 to 30 μg/ml (Additional
file 1: Figure S1C and D).
Next we tested the ability of the 5′ Prox-Oligo-
conjugated anti-GST antibody and 3′ Prox-Oligo-
conjugated anti-EGFR antibody pair to detect an
interaction between the GST-SH2 and EGFR in A431
lysate. Among multiple attempts performed to optimize
the binding conditions, we found two distinct methods
that provided a favorable signal-to-noise profile (Fig. 1b &
Additional file 1: Figure S2). In Method 1, antibodies are
premixed with target proteins prior to SH2 binding, while
in Method 2, GST-SH2 domains and EGFR (lysate) areincubated prior to antibody binding (See Methods for
more details). As the results from both methods were
nearly equivalent, Method 1 (Fig. 1b) was used for all
experiments described in this report.
Specificity of the SH2-PLA
A431 cell lysates were prepared in the presence or
absence of EGF stimulation and the SH2-PLA assay was
performed as outlined in Fig. 1b. We employed several
SH2 domain containing proteins for validation that are
known to be physiological ligands of EGFR such as
Grb2, Vav2, and PLCγ1 [26–28]. Figure 2a shows a
representative real-time PCR amplification plot of the
SH2-PLA assay using the Grb2 SH2 domain probe and
A431 cell samples. PCR product in the EGF-stimulated
A431 sample was amplified more rapidly than in the
unstimulated sample resulting in a lower threshold cycle
(Ct) value. The difference in Ct values between the two
samples (ΔCt) is an indicator of enhanced binding by
the Grb2 SH2 domain probe to tyrosine phosphorylated
EGFR (pEGFR). To validate the specificity of the assay,
we compared signal from a GST-SH2 domain probe and
GST control. The Ct value for the GST control was
unchanged with EGF stimulation (lanes 1 vs. 2, Fig. 2b
upper panel). On the other hand, the SH2 domains of
Grb2 and PLCγ1 showed a marked reduction in their Ct
values upon stimulation (lanes 5 vs. 6 and 9 vs. 10).
Using the same set of samples and SH2 domains, far-
Western blotting was performed as a reference (Fig. 2b
middle panel). In far-Western, proteins were separated
on polyacrylamide and transferred to a nitrocellulose
Fig. 2 Validation of the SH2-PLA assay. a, Representative PCR amplification plot for SH2-PLA experiments. Increased binding between SH2 and
pEGFR upon EGF stimulation is expressed as a reduced threshold cycle value (Ct). Here, ΔCt is defined as [Ctcontrol – CtEGF stimulated]. b, Specificity
of SH2-PLA. SH2-PLA (top panel) and far-Western (middle panel) results for EGF-stimulated and control A431 cell samples are shown. Results for
GST control probe are shown in lanes 1–4; Grb2 SH2 probe in lanes 5–8; and PLCγ1 tandem SH2 probe in lanes 9–12. Lanes 3, 4, 7, 8, 11, and 12
show the assay result in the presence of pY1068 blocking peptide, which contains the Grb2 SH2 consensus binding site of EGFR. c, SH2-PLA assay
performance. The SH2-PLA assay was performed three times using a two fold dilution series of EGF-stimulated and control A431 cell lysates.
Average Ct values, normalized to non protein control (NPC), are shown in the upper panel. The intra-assay variation for Ct values was 0.07-2.36
(mean 0.60) and the inter-assay %CV was 0.32-3.08 (mean 1.28). Since EGF-stimulated samples always showed a greater signal (lower Ct) than the
unstimulated control throughout the dilution series, the range of assay detection is estimated to be at least 1.1–1100 μg/ml of lysate concentration,
and the lower limit of detection is approximately 2 ng of protein per assay. The lower panel shows the approximately linear region of the mean Ct plot
against log input lysate concentrations, and the ΔCt (unstimulated – stimulated) of about three cycles. The log2 fold change between EGF-stimulated and
control samples was estimated to be 6.0 - 6.4 using the ProteinAssist software tool (Additional file 1: Figure S3). d, Adoption of other phosphotyrosine
recognizing domains. The SH2-PLA methodology was applied to protein tyrosine phosphatase (PTP) and phosphotyrosine binding (PTB) domains. ShcA
PTB domain and the substrate-trapping mutant of PTP1B PTP domain displayed activity comparable to Grb2 SH2 (lanes 1–4 and 7–8). Signal was
undetectable for the wild type (wt) PTP1B PTP domain, likely due to the intrinsic phosphatase activity (lanes 5–6)
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GST-SH2 domains [23]. The identity of a major band at
approximately 180 KDa in the SH2-far-Western blotting
has previously been confirmed to be EGFR by anti-
EGFR immunodepletion (data not shown). As shown in
the middle panel of Fig. 2b, the signal profiles of the
SH2-PLA and far-Western are similar despite their use
of distinctive assay readouts (Ct values vs. bands). SH2
domains are known to have both unique and overlap-
ping ligand binding characteristics [7, 29–32]. To deter-
mine if the SH2 binding is tyrosine site dependent, asynthesized phosphopeptide corresponding to EGFR
tyrosine 1068, containing the Grb2 SH2 consensus binding
site, was added as a blocker. In both assays, Grb2 SH2
binding was significantly reduced in the presence of the
blocker, while the blocking effect on PLCγ SH2 domain
binding was relatively modest (lanes 6 vs. 8 and 10 vs. 12).
Taken together, these results indicate that, like far-
Western, the SH2-PLA assay performed with the anti-GST
5′ Prox-Oligo antibody and anti-EGFR 3′ Prox-Oligo anti-
body probe pair is specific enough to distinguish between
EGF-stimulated and control cell samples.
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To evaluate assay performance, including the limit of
detection, linearity, and precision, we performed the
SH2-PLA assay using a serial dilution of lysate. In a 96
well plate, EGF-stimulated and control A431 cell lysates
at concentrations between 1.1 and 1100 μg/ml were
incubated with the Grb2 SH2 probe. Surprisingly, at all
11 lysate concentrations tested, EGF-stimulated samples
showed a greater signal (lower Ct value) than unstimu-
lated samples, demonstrating the high sensitivity of the
system (limit of detection: ~1 μg/ml or 2 ng protein
per assay). However, at higher lysate concentrations
(>300 μg/ml), suppressed signal was observed (Fig. 2c
upper panel), consistent with other reports using homoge-
neous proximity ligation assays [12, 19, 22]. This is often
referred to as the “high-dose hook effect” and has been
observed in other antibody based assays [33–35]. As a
result, the assay had a linear signal response range of a
1–2 order of magnitude (Fig. 2c lower panel). In
addition, the slopes of stimulated and unstimulated
samples, an indicator of PCR amplification efficiency,
were slightly different suggesting that conventional
ΔΔCt or standard curve methods are not suitable for
relative quantification of SH2 binding. Therefore, we
utilized ProteinAssist, a software tool designed for fold
change estimation in TaqMan Protein Expression Assays
based the ΔCt squared method [12]. With this method,
the log2 fold change between EGF-stimulated and control
samples was estimated to be 6.0 - 6.4 (Additional file 1:
Figure S3). Based on three independent assays, the intra-
assay variation of ΔCt values was 0.07-2.36 (mean 0.60)
and the inter-assay %CV was 0.32-3.08 % (mean 1.28 %).
Taken together, these results suggest that the limit of de-
tection and precision are favorable, but the linear signal
response range is modest, likely due to the binding charac-
teristics of antibodies and probes.
Application to other pTyr recognition domains
In addition to SH2 domains, members of the phospho-
tyrosine binding (PTB) and tyrosine phosphatase (PTP)
domain families are also known to recognize phospho-
tyrosine residues and play regulatory roles in tyrosine
kinase pathways [1, 36, 37]. Considering their potential
applications in phosphoproteomics research, we tested if
the same SH2-PLA methodology is applicable to these
domains. GST-fusion proteins of the ShcA PTB domain,
wild type PTP1B PTP domain, and catalytically inactive
(substrate-trapping) mutant PTP1B PTP domain were
purified and subjected to the assay using the same
protocol as for SH2 domains. As shown in Fig. 2d, ShcA
PTB and the catalytically inactive PTP domain of PTP1B
showed binding activity to pEGFR comparable to the
Grb2 SH2 domain, while the wild type PTP domain,
having intrinsic PTP activity, showed no binding.Estimation of EGFR phosphotyrosines at the limit of
detection
The serial dilution experiment indicated that the limit of
detection is about 2 ng protein per assay in the case of
A431 cells, although this threshold could change for
other cell lines with different EGFR expression levels. A
titration experiment using a “spike-in” pEGFR protein
control would address the ambiguity, but preparation of
such a reagent is challenging. Therefore, we took a retro-
spective approach in which a series of quantification
methods were combined to measure the absolute amount
of EGFR phosphotyrosine in the minimum amount of cell
lysate necessary for SH2-PLA.
First, using a baculovirus expression system, we gener-
ated recombinant GST fused c-Abl protein to serve as
the standard for phosphotyrosine. Then we treated the
Abl protein with the tyrosine specific phosphatases PTP1B
and TC-PTP. Anti-phosphotyrosine blots of treated and
untreated Abl proteins indicated that phosphorylated Abl
protein was mostly dephosphorylated by phosphatase
treatment. Following the treatment, we quantified the
amount of free phosphate, which is the hydrolyzed prod-
uct of phosphotyrosine, using a phosphate standard curve
generated with a malachite green phosphatase assay (ΔAbl
PO4
3− = 5.7 pmol/μg, Fig. 3a).
Next, anti-phosphotyrosine dot blotting was per-
formed and the amount of total phosphotyrosine in
EGF-stimulated Cos 1 lysate was estimated using the
Abl standard (Fig. 3b). Finally, the tyrosine phosphoryl-
ation of EGFR was estimated by comparing the EGFR
band intensity with the whole band intensity on an anti-
phosphotyrosine Western blot (Additional file 1: Figure S4).
According to these analyses, we estimated that 0.122
pmol phosphotyrosine is present on EGFR in 1 μg of
EGF-stimulated A431 cell lysate. Thus in 2 ng lysate,
which is the quantification limit of SH2-PLA (Fig. 2b),
there is 0.243 fmol of phosphotyrosine on EGFR (Fig. 3b).
In addition, assuming that A431 has 2.5 million EGFR per
cell [38–40] and 150 pg of total protein per cell [41], we
estimated that on average 4–5 tyrosines out of 22 putative
tyrosine phosphorylated sites [42] per EGFR molecule are
phosphorylated in EGF-stimulated A431 cells (Additional
file 1: Figure S4).
Practical limit of detection from cell culture
Since the lysate dilution experiment indicated that the
lysate requirement for SH2-PLA is very low, we next de-
termined the lower limit of the assay by cell numbers.
Serially diluted A431 cells were seeded in a 96-well plate,
starved 16 h, and stimulated with EGF. Cells were lysed
in the same volume of buffer and interaction between
EGFR and Vav2 SH2 was analyzed by SH2-PLA. As
shown in Fig. 4a, the assay detected EGF dependent SH2
interaction in the lysate equivalent of 16 cells (780 cells
Fig. 3 Estimation of EGFR phosphotyrosines at the limit of detection. To define an absolute lower limit of detection (LOD) for SH2-PLA, the total
amount of EGFR phosphotyrosines in sample cell lysate was estimated using a phosphotyrosine standard sample and quantitative dot blotting
analyses. a, Recombinant c-Abl protein, the pTyr-standard sample, was treated with tyrosine specific phosphatases PTP1B and TC-PTP. The amount
of hydrolyzed phosphotyrosine was quantified by malachite green phosphatase assay (ΔAbl PO4
3−). Left panel shows anti-Abl and anti-phosphotyrosine
blots for phosphatase-treated (Abl PTP+) and -untreated (Abl PTP-) samples. After the PTP treatment, the level of c-Abl tyrosine phosphorylation was
greatly reduced but weak phosphorylation was still detectable with longer exposure time. The right panel shows a plot of the phosphate standard
used for the quantification. Red circle, untreated c-Abl; blue circle, PTP-treated c-Abl; yellow circles, the kit supplied phosphate standard. From this
analysis, ΔAbl PO4
3 was estimated to be 5.7 pmol per μg of the c-Abl protein. b, Quantitative dot blotting. The total pTyr in the EGF-stimulated Cos1 cell
lysate was estimated from a pTyr standard curve generated from anti-phosphotyrosine dot blotting. Upper panel shows raw anti-Abl and anti-pTyr
blots. Serially diluted c-Abl pTyr standard (left to right 3.1–0.02 ng per spot) and 0.01 μg EGF-stimulated Cos1 samples were spotted on nitrocellulose
membrane (performed in triplicate). The middle panel shows the resulting pTyr standard plot with the quantified signal intensities. The pTyr amount in
the EGF-stimulated Cos1 lysate was estimated to be 0.08 pmol per μg lysate. Subsequently, an anti-pTyr Western analysis for A431 and Cos1 samples
was performed, relative intensities of the EGFR bands were calculated, and the amount of EGFR pTyr in the EGF-stimulated A431 sample was estimated
to be 0.122 pmol/μg. Thus 2 ng of EGF-stimulated A431 sample, which is the lower limit for SH2-PLA detection, would contain 0.243 femtomole EGFR
pTyr. See Methods and Additional file 1: Figure S4 for more information
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close to the detection limit calculated above (Fig. 2c). In
addition to EGFR-overexpressing A431 cells, we perfor-
med a similar lysate dilution experiment using EGF
stimulated Cos1 cells and found that a lysate concen-
tration approximately four times higher is required for
detection, consistent with modest EGFR phosphorylation
in Cos1 cells (Additional file 1: Figure S4 and data not
shown). These results demonstrate that SH2-PLA is cap-
able of detecting interaction between SH2 domains and
pEGFR using a very small number of cultured cells.
Correlation between SH2-PLA and far-Western in kinetic
analyses
Defining phosphorylation kinetics in growth factor stim-
ulated cells is important in cell signaling studies. We
applied the SH2-PLA approach to determine time-
dependent and dose-dependent changes in SH2 binding
to pEGFR using A431 and Cos1 cells (Fig. 4b). For
cross-validation, we performed far-Western analysis and
compared the results side by side. As shown in Fig. 4b,
the dose- and time-dependent increases in Grb2 SH2
binding to EGFR were obvious both by far-Western(~180 KDa band on upper panel) and SH2-PLA (Ct
value in lower panel). When corresponding signal values
(band intensity and Ct values) of both assays were com-
pared, there was a high correlation (Pearson coefficient
r = 0.97) (Fig. 4c). These results suggest that SH2-PLA is
capable of analyzing cells with various levels of EGFR
expression and is able to produce quantitative results
similar to those obtained from established protein-protein
interaction assays (e.g., pull-down and immunoprecipi-
tation) in a significantly shorter assay time while using
10–100 times less sample.
Application of SH2-PLA for cancer tissue analysis
To explore the translational application of SH2-PLA, we
analyzed binding of Grb2 SH2 to EGFR in lung cancer
patient tissues. Empirically, the tyrosine phosphorylation
analysis of patient-derived solid tumors is challenging
due to intrinsically high protease and phosphatase activ-
ities requiring phospho-enrichment and larger starting
material [43]. We asked if SH2-PLA is capable of detect-
ing a specific signal within human lung cancer tissues
without pTyr enrichment. In collaboration with the
Haura group at the Moffit Cancer Center, we obtained
Fig. 4 Applications of SH2-PLA assay. a, Practical limit of detection from cell culture. Two-fold serial dilutions of A431 cells were seeded to wells
in a 96-well plate. Image series shows various 10x magnifications of diluted A431 cells with cell number indicated. Vav2 SH2:pEGFR interaction of
starved or EGF-stimulated cell lysates was quantified by the SH2-PLA assay to resolve the assay detection limit. The Ct values from real-time PCR
are shown with approximate numbers of cells per culture well or per assay (in brackets) underneath the chart. b, Time course and dose response
of EGF stimulation. A431 and Cos1 cells were starved and stimulated with EGF at various times and concentrations as indicated. Upper panel
shows far-Western blotting with Grb2 SH2 (25 μg lysate loaded per lane) and control blotting with anti-actin. Bottom panel shows Ct values of
comparable SH2-PLA experiments loading 0.4 μg lysate per assay well. c, Correlation between far-Western and SH2-PLA assay. Using experimental
results shown in B, EGFR band intensities of far-Western blot (X-axis) and average Ct values of SH2-PLA (Y-axis) in panel B were plotted and
showed strong correlation. a.u., arbitrary unit; r, Pearson correlation coefficient. d, Application of SH2-PLA for cancer tissue analysis. The SH2-PLA/
Western/far-Western analyses were performed using 10 lung cancer tissue samples. Upper panel shows Western and far-Western results with
antibody/probe names indicated on the left. Only one sample (#3) shows an EGFR size band which also overlapped with bands detected by
anti-pTyr and Grb2 SH2 (far-Western image represents 60-min exposure). The tyrosine phosphorylation level of the band is similar to the weak
phosphorylation of EGFR in unstimulated A431 cells (right panel). The PLA-SH2 results for the same set of lung cancer samples are shown on the
bottom. Consistent with the Grb2 far-Western result, only sample #3 had significant signal beyond the no protein control (NPC). The BG line
indicates the background Ct value
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manner (neither molecular nor pathological character-
istics were provided). We lysed the frozen tissues and
performed the SH2-PLA assay (with the Grb2 SH2-
anti EGFR probe pair), Western blotting (with anti-
phosphotyrosine antibody), and far-Western blotting
(with Grb2 SH2 probe) for comparison (Fig. 4d). In
Western and far-Western, only one sample showed tyro-
sine phosphorylation at a band corresponding to EGFR
size (#3, upper and middle panels). In the SH2-PLA assay
using 0.5 μg of lysate per assay (equivalent to ~3,000 cells),
we also observed a modest but significant signal (lower Ct
value) in the same sample confirming the presence oftyrosine phosphorylated EGFR (lower panel), even though
its level of phosphorylation was significantly lower than
that of A431 cell samples (upper right panel). This result
indicates that SH2-PLA is capable of detecting tyrosine
phosphorylated SH2 domain recognition sites in weakly
phosphorylated tumor tissues without requiring phospho-
peptide enrichment.
Discussion
In this study we developed SH2-PLA, a novel in-
solution SH2 domain binding assay, to analyze tyrosine
phosphorylated EGFR in EGF-stimulated cells. The key
feature of this assay is that binding of the SH2 domain
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monitored in solution using a combination of proximity
ligation and quantitative PCR technologies. A positive
signal requires the formation of a quaternary protein
complex, namely a 5′ oligonucleotide-tagged anti-
GST antibody (anti-GST 5′ Prox-Oligo probe), a GST-
SH2 protein, tyrosine phosphorylated EGFR, and a 3′
oligonucleotide-tagged anti-EGFR antibody (anti-EGFR 3′
Prox-Oligo probe). We identified two stepwise protocols
which yielded a suitable signal-to-noise profile: Method 1,
pre-incubation of antibody probes to their respective
targets (EGFR and GST) followed by SH2 binding; and
Method 2, pre-incubation of the SH2 probe with EGFR
followed by antibody binding. For EGF-stimulated A431
cells, we showed that a signal is detectable with as little as
2 ng lysate input per reaction and that the assay is able to
detect specific interactions across three orders of magni-
tude of lysate input. To test the practical application, we
conducted phosphorylation kinetics experiments of EGF-
stimulated cells and observed good agreement between
SH2-PLA and the established far-Western assay. Further
we showed that SH2-PLA unambiguously detected a rela-
tively low level of EGFR phosphorylation in lung cancer
tissues using far less cell lysates than typically available
from a core needle biopsy (~105 cells or 100 μg) [44].
These data suggest that SH2-PLA is a promising platform
to rapidly determine SH2 domain binding sites in EGF-
stimulated cells or cancer tissues using a small amount of
sample.
As with other immunoassays such as ELISA and bead
arrays, various types of SH2 and other modular domain
binding assays in both solid- and solution-phase plat-
forms have been described [2, 45]. Among those, pull
down, far-Western and their derivatives represent the
most popular methods to assess SH2 domain binding
sites on target proteins (e.g., pEGFR). In pull down as-
says, lysate is incubated with bead-bound SH2 domains
for several hours, followed by Western blotting with spe-
cific antibodies to the target protein. This assay requires a
rigorous washing step and a negative control to minimize
signal from non-specific binding and can be confounded
by indirect binding via multi-protein complexes. In far-
Western blotting, only direct binding between the labeled
SH2 domain and membrane-bound proteins is detected,
though the identity of the band may need to be confirmed
by immunoprecipitation or other methods. As a result of
these multiple procedures, these assays are usually low
throughput, requiring 100–1000 μg of protein and mul-
tiple days of assay runtime. In contrast, SH2-PLA requires
only a few microliters of lysate and 6–7 hours of assay
time, making this assay highly flexible. Although other
high throughput systems, based on microarray or fluores-
cence polarization, are suitable for global mapping of SH2
domain binding sites using synthesized peptide libraries[29, 32, 46, 47], SH2-PLA excels in the detection of SH2
binding to a specific target protein in whole cell lysate
without requiring pre-purification or enrichment.
Although the assay sensitivity is high, we observed a
relatively modest linear range (1–2 orders of magnitude).
It is currently unknown that whether this can be attrib-
uted to biochemical characteristics of assay components
including buffer solutions, oligonucleotides, antibodies,
GST-SH2 domains, and the stoichiometry of tyrosine
phosphorylation sites on EGFR. Consistent with our ob-
servation (Additional file 1: Figure S1A), the linear range
for the TaqMan Protein assay system is reported to be
2–3 orders of magnitude when used to quantify protein
expression [12, 20]. The anti-EGFR and GST antibodies
used in this study when tested individually showed a
lower linear range (Additional file 1: Figure S1C and D).
In addition, the SH2-PLA, designed to detect the forma-
tion of the quaternary protein complex, may also be af-
fected by the transient nature of SH2 domain-ligand
binding [48–50]. Thorsen et al. have reported a feasibil-
ity study correlating the MMP9:TIMP1 protein complex
with breast cancer prognosis in which they validated the
use of ELISA and PLA-based methods [51]. In this report,
they obtained a linear signal range across approximately
one order of magnitude in human plasma dilutions (10X
to 100X dilution). Taken together, multiple factors might
result in the relatively narrow linear range seen in these
protein-protein interaction assays employing in-solution
proximity ligation assay. Nevertheless, this issue can be
partly addressed by calibration using software tools such
as ProteinAssist [12] (Additional file 1: Figure S3). More-
over, in many cases protein interaction assays are qualita-
tive rather than quantitative in which the identification of
positive interactions is the priority and high sensitivity and
wide detection range, such as that observed in SH2-PLA,
is essential.
Performance of SH2-PLA could be improved by modi-
fying the methodology. Firstly, direct labeling of SH2
domains or the GST tag with oligonucleotides would
reduce the assay complexity and could prevent issues
stemming from insufficient GST:anti-GST antibody
binding. Further, if different SH2 domains are tagged
with different oligonucleotides, it would allow for a
multiplex PLA reaction analogous to the previously
described competitive reverse-phase SH2 profiling assay
[8]. A potential problem with direct tagging is SH2
domain activity loss due to amino acid modification that
would need to be assessed on a domain-by-domain basis.
Secondly, solid-phase PLA could be considered. Solid-
phase PLA uses an additional antibody which captures the
target prior to dual recognition with 3′ and 5′ PLA anti-
body probes [14]. Solid-phase PLA was reported to have a
broader dynamic range compared to solution-phase PLA
[52, 53]. Owing to its additional washing steps, solid-
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unbound PLA probes and interfering substances in the
buffer. 4-PLA, a more elaborate variation of solid-phase
PLA, is another choice [54]. In 4-PLA, a set of five anti-
bodies consisting of one capture antibody and four
oligonucleotide-bound antibodies are employed to attain
simultaneous recognition of five epitopes on one or more
target molecules. Tavoosidana et al. applied 4-PLA to
quantification of prostasome microvesicles, a potential
marker of prostate malignancies, in blood samples and
showed superior performance over a conventional PLA. A
tempting application of this method would be a multiplex
modular domain assay targeting multiple PTMs on recep-
tor tyrosine kinases such as EGFR or PDGFR. Receptor
PTMs could be monitored by a set of PTM-recognizing
domains, e.g., SH2, 14-3-3, etc., allowing for identification
of exclusive or simultaneous modifications. The lower
background of these solid phase platforms could benefit
SH2-PLA with improved overall sensitivity. However add-
itional binding and washing steps will compromise the
simplicity of the current SH2-PLA method. More import-
antly, it remains to be determined if weak SH2-pTyr inter-
actions would be detectable after a stringent wash.
In addition to the SH2 domain, we demonstrated that
this PLA-based methodology is a promising platform for
the interrogation of other domain-based interactions.
We showed that PTB and substrate-trapping PTP do-
mains are capable of detecting EGFR phosphorylation.
Although the SH2 domain is the most prevalent type of
phosphotyrosine binding domain, integration of these
other domains into the phosphorylation profiling is advan-
tageous in that they allow for a larger coverage of tyrosine
phosphorylation sites.
One obstacle to developing a customized SH2-PLA
method for phosphorylated proteins will be preparation
of a positive control. The original TaqMan Protein Assay
is designed to quantify protein expression, making a
purified protein target the most suitable control for de-
termining assay performance. However, in the case of
the SH2-PLA, a protein interaction assay assessing phos-
phorylation of a target protein, preparation of a suitable
control is not a trivial task. For example, since SH2 do-
mains may bind to a multiple tyrosine phosphorylation
sites on the target protein, an appropriate positive con-
trol suitable for spike-in experiments should be phos-
phorylated on all SH2 binding sites and contain the
antibody binding motif. We sidestepped this issue by es-
tablishing tyrosine phosphorylation standards and quan-
tifying the absolute amount of tyrosine phosphorylation
in the given sample, thereby estimating the assay detec-
tion limit. While this approach is applicable to any tyro-
sine phosphorylated protein target, similar approaches
could also be tailored for other domains recognizing
post-translational modification sites on cellular proteins[55]. This feature as well as the universality of GST-
tagging could allow SH2-PLA to serve as a prototype
for the development of powerful, convenient modular
domain based proteomic tools [45].
Conclusions
We have developed SH2-PLA, an alternative in-solution
homogenous SH2 domain binding assay based on prox-
imity ligation and real-time PCR. Using SH2-pEGFR in-
teractions as the assay target, we showed that SH2-PLA
has sufficient specificity, a very low limit of detection, a
1–2 order of magnitude linear range, and high reprodu-
cibility. In experiments with various EGF-stimulated
cells, we confirmed good agreement between SH2-PLA
and established far-Western assay results. Further, we
found that SH2-PLA is sensitive enough to detect the rela-
tively low level of pEGFR in lung cancer tissues without
enrichment of pTyr-containing proteins. To our know-
ledge, this is the first report describing a microliter-scale
assay for the detection of interaction between a recom-
binant SH2 domain probe and EGFR in cell lysate. This
method provides significant improvement over traditional
protein interaction assays requiring large sample input.
With the low sample requirement and short assay run-
time, SH2-PLA can provide a useful platform on which to
develop high throughput modular domain binding assays
applicable in both basic and translational cancer research.
Methods
Cell culture and sample preparation
Epidermoid carcinoma cell line A431 and monkey kidney
fibroblast-like cell line Cos1 were maintained in DMEM
supplemented with 10 % fetal bovine serum and 0.1 %
penicillin/streptomycin (Mediatech). For EGF stimulation,
overnight starved cells were stimulated with 50 ng/ml
(0.37 nM) human recombinant Epidermal Growth Factor
(EGF, Millipore Upstate) for 5 min and immediately lysed
in Sample Lysis buffer (Applied Biosystems) with 1 mM
phenyl methyl sulfonyl fluoride (PMSF), 1 mM sodium
orthovanadate, and 5 μg/ml Aprotinin (Sigma A6279). For
the cell titration experiment (Fig. 4a), two-fold serial dilu-
tions ranging from 48 to 5 × 104 A431 cells were seeded in
a 96-well plate. Cells were starved for 16 h, stimulated
with EGF, harvested, and lysed in 50 μl of the Cell Lysis
Reagent (Applied Biosystems) with 1 mM PMSF, 1 mM
sodium orthovanadate, and 5 μg/ml Aprotinin. Cleared
lysates were used in SH2-PLA assay with the Vav2 SH2
domain. For time course and dose response experiments
(Fig. 4b), cells were stimulated at different times (0–300 s)
and doses (0–200 ng/ml). Immediately after stimulation,
culture media was poured off and the dishes were snap
frozen in liquid nitrogen. Frozen dishes were incubated
with 300 μl Sample Lysis Buffer. Non small cell lung can-
cer tissues, originally banked at the Moffitt Cancer Center
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(Moffitt Cancer Center) without clinical or biochemical
information. The OCT-embedded frozen tissues were
crushed, lysed in Sample Lysis Buffer, and solubilized
using the Cryoprep and S2 homogenizer systems (Covaris).
Cleared lysates were stored at −80 °C.
GST fusion constructs
GST fusion proteins containing the Grb2 SH2 (amino
acids 58–159), PLCγ1 SH2-SH2 (542–759), Vav2 SH2
(665–774), and ShcA PTB (127–317) were prepared as
previously described [23]. Briefly, bacterial culture was
incubated with 0.1 mM isopropyl β-D-1-thiogalactopy-
ranoside (IPTG) and incubated at 16 °C for 24 h. After
harvesting bacteria, proteins were affinity-purified on
glutathione-Sepharose beads. Protein concentration was
determined by Bradford assay (Bio-Rad), purity of pro-
tein was confirmed by SDS-PAGE, concentration was
adjusted to 0.1 μg/μl with 10 % Glycerol-PBS, and stored
at −80 °C. Similarly tyrosine phosphatase domain cDNA
for human PTP1B (1–321, wild type and substrate trap-
ping D181A mutant) and TC-PTP (1–354, wild type),
both gifts from M.L. Tremblay, McGill University, were
inserted into pGEX-6P1 (GE Healthcare), expressed in
bacteria, purified, and stored at −80 °C.
Western and far-Western blotting
25 μg (A431 and Cos1) or 40 μg (lung cancer tissues) of
lysates were separated by SDS-PAGE and transferred to
nitrocellulose membranes. Far-Western and Western
blotting analyses were carried out as previously described
[6, 7, 23]. Replica membranes were incubated with 200
nM GST fusion proteins in 5 % fat-free milk dissolved in
TBST (150 mM NaCl, 10 mM Tris–HCl [pH 8.0], and
0.05 % Tween-20) for 2 h, washed for 20 min, and specific
bands were visualized by chemiluminescence. Blots were
stripped and reprobed with anti-EGFR (Santa Cruz
Biotechnology), anti-phosphotyrosine (Cell Signaling), and
anti-actin (Santa Cruz Biotechnology) antibodies. For
quantitative far-Western analysis (Fig. 4b), band intensities
were quantitated using ImageJ densitometry software
(National Institutes of Health). For estimation of the
absolute amount of tyrosine phosphorylation (Fig. 3 and
Additional file 1: Figure S4), anti-phosphotyrosine Western
blots were quantified using the LI-COR Odyssey IR detec-
tion system (LI-COR Biosciences).
ICAM1 protein expression assay
Under the test site agreement, the TaqMan Protein
Expression Assay kit was supplied from Applied Biosys-
tems, part of Life Technologies. The supplied items in-
cluded ICAM1 PLA assay probes; Raji B-cell lymphoma
control lysate; Lysate Dilution Buffer; Assay Probe Dilution
Buffer; Ab/Prox-Oligo Dilution Buffer; Assay Probe StorageBuffer; 5′ Prox-Oligo; 3′ Prox-Oligo; DNA ligase; Ligation
Dilution Buffer; Ligation Reaction Buffer; protease; Uni-
versal PCR Assay; Fast Master Mix; Cell Lysis Reagent;
Cell Resuspension Buffer; and an assay protocol. Add-
itional reagents required for the assay were purchased
from Applied Biosystems or other suppliers.
The Raji cell lysate (250 cell equivalent per μl) was
serially 2-fold diluted in the Lysate Dilution Buffer in a
96-well plate on ice. 2 μl of 0.5 nM 3′ and 5′ ICAM1
assay probe mixture was added to 2 μl lysate in quadru-
plicate, sealed with MicroAmpTM Clear Adhesive Film,
and incubated for 60 min at 37 °C. Subsequently 96 μl of
DNA ligase in Ligation Dilution Buffer was added to the
sample wells, resealed and incubated at 37 °C for 10 min
to allow for the ligation reaction. The reaction was stopped
by adding 2 μl of diluted protease solution to each well and
the sealed plate was incubated at 37 °C for 10 min followed
by heat inactivation at 95 °C for 5 min.
For real-time PCR reactions, 9 μl of the ligation prod-
uct was mixed with 1 μl Universal PCR Assay solution
and 10 μl of TaqMan Protein Expression Fast Master
Mix in a real time PCR reaction plate. The ligation plate
was sealed with MicroAmp Optical Adhesive Film, cen-
trifuged at 1000 rpm for 10 s, and real-time PCR was
performed using the StepOnePlus System with fast cyc-
ling condition (Applied Biosystems). The real-time PCR
data including Ct values at threshold 0.2 with automatic
baseline setting were exported from StepOne software
and plotted by Ct values (cycle) and lysate input (cell
equivalent per μl). Intra-assay variation was assessed
using %CV of quadruplicates and inter-assay by Pearson
correlation using Prism 6 software (GraphPad). For linear-
ity assessment, Ct values were fitted by log-linear regres-
sion and R-squared values were calculated.
Anti-GST and anti-EGFR probe development
Conjugation of biotinylated antibodies and oligonucleotide
tags (5′ and 3′ Prox-Oligos) was carried out following the
TaqMan Protein Expression Assay Probe Development
Protocol (Applied Biosciences). To generate the anti-EGFR
3′ (or 5′) SH2-PLA probe, biotinylated anti-human EGFR
antibody BAF231 (R&D Systems) was incubated with 3′
(or 5′) Prox-Oligo at 200 nM in Ab/Prox-Oligo Dilution
Buffer at room temperature for 1 h with gentle rocking.
The resulting 3′ anti-EGFR probe was diluted to 10 nM
with Assay Probe Storage buffer and stored at −20 °C. The
anti-GST 5′ (or 3′) SH2-PLA probe was prepared in
the same manner using a biotinylated anti-GST antibody
A00202 (Genscript) and 5′ (or 3′) Prox-Oligo.
To test the activity of the anti-GST 5′ and 3′ SH2-
PLA probes, GST protein, purified and stored in −80 °C
at 0.1 μg/μl in 10 % glycerol-PBS, was adjusted to 0.1 ng/μl
with Cell Resuspension Buffer and 2-fold serially diluted
in a 96-well plate on ice. The anti-GST 5′ and 3′ SH2-
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The same volume of anti-GST 5′ and 3′ SH2-PLA probes
were gently mixed, and 2 μl of mixed assay probes were
added to 2 μl of serially diluted GST protein in duplicate
(GST concentration: 0.13 nM – 4.17 nM). To test the
activity of anti-EGFR SH2-PLA probes, protein lysates of
50 ng/ml EGF-stimulated and control A431 cells were ad-
justed to 0.03 μg/μl with Cell Resuspension Buffer and
then 2-fold serially diluted in a 96-well plate on ice. 5′ and
3′ anti-EGFR Prox-Oligo probes were diluted in Assay
Probe Dilution Buffer. The equal volumes of the 5′ and 3′
probes were gently mixed, and 2 μl of the mixture was
added to 2 μl of serially diluted lysate in duplicate (final
concentration of 0.93 – 30 μg/ml). Subsequent ligation
reaction, protease treatment and real-time PCR were per-
formed as described for the “ICAM1 protein expression
assay.” In these experiments, the Ct value for unstimulated
A431 lysate in a combination with anti-GST 5′ and anti-
EGFR 3′ probes was used as a negative control (NC). The
pY1068 blocker peptide for the Grb2 binding site on
EGFR was purchased from Cell Signaling.
SH2-PLA assay
Method 1: Lysate dilutions in Cell Resuspension Buffer
were incubated with anti-EGFR 3′ PLA Prox-Oligo probe
(final concentration 0.5 nM) for 1.5 h at 4 °C [Solution 1].
GST-SH2 protein was incubated with anti-GST 5′ Prox-
Oligo probe (final concentration 0.1 μg/ml and 0.5 nM,
respectively) for 1.5 h at 4 °C [Solution 2]. Then 2 μl of
the Solution 1 and Solution 2 were incubated at 4 °C for
1.5 h in the thermal cycler to induce a quaternary
complex of [anti-EGFR 3′Prox-Oligo probe:phospho-
rylated EGFR:GST-SH2 protein:anti-GST 5′ Prox-Oligo
probe] (Fig. 1b). Subsequent ligation reaction, protease
treatment and real-time PCR were performed as described
for the “ICAM1 protein expression assay.”
Method 2: GST-SH2 or GST control proteins were
diluted to 0.1 μg/ml in Cell Resuspension Buffer and in-
cubated with the same volume of EGF-stimulated or un-
stimulated cell lysate for 1.5 h at 4 °C (for SH2-EGFR
binding). Then 2 μl of the SH2 bound lysates were incu-
bated with 2 μl of 0.5 nM Prox-Oligo probe mixture
(anti-GST 5′ + anti-EGFR 3′) in a thermal cycler at 4 °C
for 1.5 h to form a quaternary complex of [anti-EGFR 3′
Prox-Oligo probe:phosphorylated EGFR:GST-SH2 pro-
tein:anti-GST 5′ Prox-Oligo probe] (Additional file 1:
Figure S2). Subsequent ligation reaction, protease treat-
ment and real-time PCR were performed as described in
“ICAM1 protein expression assay.”
Quantification of EGFR phosphotyrosines
A GST fusion of wild-type murine type IV c-Abl was
produced from baculovirus-infected Sf9 insect cells as
described previously [24]. GST-Abl was purified byincubating lysates with glutathione-agarose beads (GE)
at 4 °C for 1.5 h, washing extensively in Buffer E (50 mM
Tris pH 8.0, 150 mM NaCl, 5 % glycerol, 2 mM dithio-
threitol) and eluting with Buffer E plus 20 mM reduced
glutathione. Prior to the malachite green free phosphate
assay, the GST-Abl solution was concentrated to about
0.5 μg/μl with an Amicon Ultra-4 Centrifugal Filter (10 K,
Millipore).
Malachite green phosphate assays were performed
according to the manufacturer’s instructions (Abnova).
Briefly, purified GST-Abl and PTP cocktail (GST-PTP1B
and GST-TcPTP) proteins are incubated at a 5:1 molar
ratio at 37 °C for 2 h, then mixed with acidic solution
for quenching. Serially diluted reactions were visualized
with 1 mM malachite green and quantified by absorbance
at 620 nM using the M1000 Pro plate reader (Tecan). A
standard curve for the absorbance and phosphate input
(PO4
3−) was obtained by adding a serially diluted free phos-
phate standard into the untreated c-Abl solution. The
change in phosphotyrosine (as assessed by PO4
3− release)
in the c-Abl solution during the PTP treatment (ΔAbl
PO4
3−) was estimated with the free phosphate standard
curve (Fig. 3a).
For comparative dot blotting, Abl proteins and Cos1
lysates were diluted in SDS sample buffer, boiled, and
manually spotted in triplicates on a nitrocellulose mem-
brane (0.003 to 100 ng in 0.5 μl per spot). The dried
membrane was incubated in Buffer T (10 mM CAPS
pH 11.0, 20 % methanol) for 30 min, blocked in 5 %
nonfat milk-TBST for 1 h, and incubated with anti-
phosphotyrosine antibody (PY100, Cell Signaling) over-
night at 4 °C. After washing with TBST (10 mM Tris
pH8.0, 150 mM NaCl, 0.05 % Tween 20), membranes
were incubated with IRdye conjugated goat anti-mouse
antibody, washed, and bound antibody was detected using
an infrared imaging system (Odyssey, LI-COR Bioscience).
Raw signal of individual dots was quantified using Odys-
sey 3.03 and ImageStudio software (LI-COR Biosciences)
and plotted against protein quantity (Fig. 3b).
The absolute amount of phosphotyrosine in the Cos1
sample, was estimated by the linear standard curve gen-
erated by serially diluting the Abl standard (Fig. 3b). Of
note, although a trace amount of tyrosine phosphoryl-
ation is detectable in PTP-treated Abl, at low concentra-
tions (3.1–0.02 ng per spot) the untreated Abl spots had
a linear signal profile and were unaffected by the trace
PTP-treated Abl signal. Thus the pTyr amount of the
target sample can be interpolated using the linear Abl
calibration curve (Fig. 3b). For EGFR band quantification,
10 μg of A431 and Cos1 cell samples were separated on
SDS-PAGE, transferred to nitrocellulose in Buffer T, and
immunoblotted with anti-phosphotyrosine antibody as
described above. For EGFR band analysis, the mean values
of whole lanes of EGF-stimulated samples were compared
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to approximate the amount of phosphotyrosine on EGFR
in A431 cells (Additional file 1: Figure S4).Data analysis and statistical tests
To evaluate assay performance, the Ct values were plotted
against the lysate concentration (μg/ml) or cell number
(cell per μl) and compared with those of unstimulated
control samples. The linear signal range was estimated
using Microsoft Excel 2011 (Microsoft), Prism 6.0 (Graph-
Pad), and ProteinAssist (Applied Biosystems) as appropri-
ate. Outliers were excluded by the ROUT method in
Prism 6.0 with Q = 1.0 % [25]. The intra-assay variation
was determined by %CV of Ct values from three technical
replicates. Assay to assay (inter-assay) variability was as-
sessed with normalized Ct values from three independent
experiments, in which antibody binding, SH2 binding,
ligation, protease treatment, and real-time PCR reactions
were independently performed while using the same batch
of cell lysate samples.
For fold change estimation, ProteinAssist v1.1 (Ap-
plied Biosystems), a software tool customized for Taq-
Man Protein Assays based on the ΔCt squared method,
was used [12]. Relative quantification was performed
using serial dilution data for EGF-stimulated and control
samples (Fig. 2 and Additional file 1: Figure S3). Raw Ct
values were directly imported into ProteinAssist which
generated the ΔCt-by-input quantity plots. The quantifi-
cation threshold, outlier detection, and linear range de-
tection were set to default values and the automatically
assigned linear range was manually corrected. The log2
fold change with 95 % confidential intervals between the
stimulated and unstimulated samples for Grb2 SH2
binding was estimated by comparing each X-intercept
(at quantification threshold set at 2.0) of the linear regions
of the ΔCt plots for the stimulated and unstimulated
samples.
For clinical samples, the statistical significance of sam-
ple Ct value differences were assessed using an ordinary
one-way ANOVA test with Dunnett’s multiple compari-
sons test using Prism 6.0.Additional file
Additional file 1: Figure S1. Performance of homogeneous in-solution
PLA. Figure S2. Experimental workflow for SH2-PLA Method 2. Figure S3.
Fold change calculation. Figure S4. SH2-PLA limit of detection estimation.Abbreviations
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